Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of Salmon Calcitonin

BMC Clinical Pharmacology

Volumn 8, Issue , 2008, Pages

  Karsdal, Morten A ^a   Byrjalsen, Inger ^a   Riis, Bente J ^a   Christiansen, Claus ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

8 (N 2 HYDROXY 5 CHLOROBENZOYL)AMINOCAPRYLIC ACID; CARBOXY TERMINAL TELOPEPTIDE; PENETRATION ENHANCING AGENT; PLACEBO; SALCATONIN; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; CALCITONIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEMALE; FLUID INTAKE; FOOD INTAKE; GASTROINTESTINAL ABSORPTION; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOAVAILABILITY; BONE; DRINKING; DRUG EFFECT; EATING; INTESTINE ABSORPTION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CROSS-OVER STUDIES; DRINKING; EATING; FEMALE; HUMANS; INTESTINAL ABSORPTION; MIDDLE AGED; TIME FACTORS;

EID: 52949084000     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-8-5     Document Type: Article

References (40)

1. Karsdal MA Tanko LB Riis BJ Sondergard BC Henriksen K Altman RD Calcitonin is involved in cartilage homeostasis: Is calcitonin a treatment for OA? Osteoarthritis Cartilage 2006, 14:617-624. 10.1016/ j.joca.2006.03.014 16698291
2. Sexton PM Findlay DM Martin TJ Calcitonin Curr Med Chem 1999, 6:1067-1093. 10519914
3. Deftos LJ Calcitonin Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 6 2006, Chapter 18 115-117.
4. Copp DH Cameron EC Cheney BA Davidson AG Henze KG Evidence for calcitonin - a new hormone from the parathyroid that lowers blood calcium Endocrinology 1962, 70:638-49. 638-649. 13881211
5. Kumar MA Foster GV MacIntyre I Further evidence for calcitonin. a rapid-acting hormone which lowers plasma-calcium Lancet 1963, 2(7306):480-482. 14065416
6. Tanko LB Bagger YZ Alexandersen P Devogelaer JP Reginster JY Chick R Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: Acute and 3-month effects on biomarkers of bone turnover J Bone Miner Res 2004, 19:1531-1538. 10.1359/JBMR.040715 15312255
7. Bagger YZ Tanko LB Alexandersen P Karsdal MA Olson M Mindeholm L Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: A new potential treatment of osteoarthritis Bone 2005, 37:425-430. 10.1016/j.bone.2005.04.032 16005273
8. Yamamoto M Tachikawa S Maeno H Effects of porcine calcitonin on behavioral and electrophysiological responses elicited by electrical stimulation of the tooth pulp in rabbits Pharmacology 1982, 24:337-345. 10.1159/000137616 7111374
9. Lee YH Sinko PJ Oral delivery of salmon calcitonin Adv Drug Deliv Rev 2000, 42:225-238. 10.1016/S0169-409X(00)00063-6 10963837
10. Torres-Lugo M Peppas NA Transmucosal delivery systems for calcitonin: A review Biomaterials 2000, 21:1191-1196. 10.1016/S0142-9612(00)00011-9 10811300
11. Buclin T Cosma RM Burckhardt P Azria M Attinger M Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers J Bone Miner Res 2002, 17:1478-1485. 10.1359/ jbmr.2002.17.8.1478 12162502
12. Sakuma S Suzuki N Sudo R Hiwatari K Kishida A Akashi M Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin Int J Pharm 2002, 239:185-195. 10.1016/ S0378-5173(02)00113-8 12052704
13. Guggi D Kast CE Bernkop-Schnurch A In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix Pharm Res 2003, 20:1989-1994. 10.1023/B:PHAM.0000008047.82334.7d 14725364
14. Wang J Chow D Heiati H Shen WC Reversible lipidization for the oral delivery of salmon calcitonin J Control Release 2003, 88:369-380. 10.1016/S0168-3659(03)00008-7 12644363
15. Bernkop-Schnurch A Hoffer MH Kafedjiiski K Thiomers for oral delivery of hydrophilic macromolecular drugs Expert Opin Drug Deliv 2004, 1:87-98. 10.1517/17425247.1.1.87 16296722
16. Lamprecht A Yamamoto H Takeuchi H Kawashima Y pH-sensitive microsphere delivery increases oral bioavailability of calcitonin J Control Release 2004, 98:1-9. 10.1016/j.jconrel.2004.02.001 15245884
17. Manicourt DH Azria M Mindeholm L Thonar EJ Devogelaer JP Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis Arthritis Rheum 2006, 54:3205-3211. 10.1002/art.22075 17009253
18. Sondergaard BC Ostergaard S Christiansen C Karsdal MA The Effect of Oral Calcitonin on Cartilage Turnover and Surface Erosion in the Ovariectomized Rat ModelI Arthritis Rheum 2007, 56(8):2674-2678. 10.1002/ art.22797 17665432
19. Van den MG Colon drug delivery Expert Opin Drug Deliv 2006, 3:111-125. 10.1517/17425247.3.1.111 16370944
20. Shareef MA Khar RK Ahuja A Ahmad FJ Raghava S Colonic drug delivery: An updated review AAPS PharmSci 2003, 5:E17. 10.1208/ps050217 12866944
21. Wiktor-Jedrzejczak W Urbanowska E Aukerman SL Pollard JW Stanley ER Ralph P Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor Exp Hematol 1991, 19:1049-1054. 1915705
22. Malkov D Angelo R Wang HZ Flanders E Tang H Gomez-Orellana I Oral delivery of insulin with the eligen technology: Mechanistic studies Curr Drug Deliv 2005, 2:191-197. 10.2174/1567201053586001 16305420
23. Streubel A Siepmann J Bodmeier R Gastroretentive drug delivery systems Expert Opin Drug Deliv 2006, 3:217-233. 10.1517/17425247.3.2.217 16506949
24. Gaudiano MC Colone M Bombelli C Chistolini P Valvo L Diociaiuti M Early stages of salmon calcitonin aggregation: Effect induced by ageing and oxidation processes in water and in the presence of model membranes Biochim Biophys Acta 2005, 1750:134-145. 15964788
25. Smoum R Rubinstein A Srebnik M Chitosan-pentaglycine-phenylboronic acid conjugate: A potential colon-specific platform for calcitonin Bioconjug Chem 2006, 17:1000-1007. 10.1021/bc050357y 16848408
26. Rosenquist C Fledelius C Christgau S Pedersen BJ Bonde M Qvist P Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clin Chem 1998, 44:2281-2289. 9799755
27. Schaller S Henriksen K Hoegh-Andersen P Sondergaard BC Sumer EU Tanko LB In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: How biomarkers can assist? Assay Drug Dev Technol 2005, 3:553-580. 10.1089/ adt.2005.3.553 16305312
28. Garcia-Fuentes M Torres D Alonso MJ New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin Int J Pharm 2005, 296:122-132. 10.1016/j.ijpharm.2004.12.030 15885464
29. Sostek MB Chen Y Andersson T Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole Br J Clin Pharmacol 2007, 64:386-390. 2000656 17425628 10.1111/j.1365-2125.2007.02889.x
30. Lentz KA Quitko M Morgan DG Grace JE Jr Gleason C Marathe PH Development and validation of a preclinical food effect model J Pharm Sci 2007, 96:459-472. 10.1002/jps.20767 17075867
31. Karara AH Dunning BE McLeod JF The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects J Clin Pharmacol 1999, 39:172-179. 10.1177/00912709922007606 11563410
32. Sogaard B Mengel H Rao N Larsen F The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects J Clin Pharmacol 2005, 45:1400-1406. 10.1177/ 0091270005280860 16291715
33. Dresser GK Kim RB Bailey DG Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides Clin Pharmacol Ther 2005, 77:170-177. 10.1016/j.clpt.2004.10.005 15735611
34. Morello KC Wurz GT DeGregorio MW Pharmacokinetics of selective estrogen receptor modulators Clin Pharmacokinet 2003, 42:361-372. 10.2165/ 00003088-200342040-00004 12648026
35. Gertz BJ Clemens JD Holland SD Yuan W Greenspan S Application of a new serum assay for type I collagen cross-linked N-telopeptides: Assessment of diurnal changes in bone turnover with and without alendronate treatment Calcif Tissue Int 1998, 63:102-106. 10.1007/s002239900497 9685512
36. Qvist P Christgau S Pedersen BJ Schlemmer A Christiansen C Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting Bone 2002, 31:57-61. 10.1016/S8756-3282(02)00791-3 12110413
37. Chapurlat RD Garnero P Breart G Meunier PJ Delmas PD Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: The EPIDOS study Bone 2000, 27:283-286. 10.1016/ S8756-3282(00)00325-2 10913923
38. Karsdal MA Henriksen K Sorensen MG Gram J Schaller S Dziegiel MH Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption Am J Pathol 2005, 166:467-476. 1602325 15681830
39. Chesnut CH III Silverman S Andriano K Genant H Gimona A Harris S A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group Am J Med 2000, 109:267-276. 10.1016/S0002-9343(00)00490-3 10996576
40. Schlemmer A Hassager C Jensen SB Christiansen C Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women J Clin Endocrinol Metab 1992 74 476 480 10.1210/jc.74.3.476 1740479